AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANNX
  4. [Form 4] Annexon, Inc. Insider Trading Activity

[Form 4] Annexon, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Filing content is currently unavailable.

Source:

Stock ANNX logo
Annexon, Inc.

NASDAQ:ANNX

ANNX Rankings

#3869 Ranked by Market Cap
N/A Ranked by Dividends

ANNX Latest News

Aug 14, 2025
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Aug 7, 2025
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
Jul 24, 2025
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
Jun 18, 2025
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
May 29, 2025
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

ANNX Latest SEC Filings

Aug 14, 2025
[10-Q] Annexon, Inc. Quarterly Earnings Report
Aug 14, 2025
[SCHEDULE 13G/A] Annexon, Inc. SEC Filing
Aug 6, 2025
[SCHEDULE 13G/A] Annexon, Inc. SEC Filing
Aug 1, 2025
[Form 4] Annexon, Inc. Insider Trading Activity
Jul 16, 2025
[Form 4] Annexon, Inc. Insider Trading Activity

ANNX Stock Data

267.70M
101.68M
0.42%
103.17%
9.53%
Biotechnology
Pharmaceutical Preparations
United States
BRISBANE